Elsevier

Biochemical Pharmacology

Volume 48, Issue 8, 18 October 1994, Pages 1605-1610
Biochemical Pharmacology

Selective inhibition of cyclooxygenase 2

https://doi.org/10.1016/0006-2952(94)90205-4Get rights and content

Abstract

Cyclooxygenase (COX), a key enzyme in the formation of prostanoids, is known to exist in two isoforms: an inducible enzyme (COX 2) and a constitutive form (COX 1). Both enzymes are inhibited by non-steroidal anti-inflammatory drugs (NSAID), but only marginal selectivity has thus far been reported. In this study, we report on a novel selective inhibitor of COX 2, CGP 28238 (6-(2,4-dinuorophenoxy)-5-methyl-sulfonylamino-1-indanone). Human washed platelets were used as a source of COX 1. For IL-1 stimulated rat mesangial cells we demonstrated the almost exclusive presence of COX 2 in western blot and mRNA analysis. Therefore these two model systems were chosen for selectivity testing. With an ic50 value of 15 nM, CGP 28238 blocked COX 2 activity in a similar concentration range to that of other potent NSAID such as indomethacin and diclofenac (ic50 = 1.17-8.9 nM). However, in contrast to these reference NSAIDs, CGP 28238 was at least 1000-fold less potent in inhibiting COX 1. Using other cell systems reported to express COX 1 or COX 2, we obtained a similar selectivity for COX 2. Thus, on the basis of our findings, CGP 28238 is a novel, highly potent and selective inhibitor of COX 2 and may be a lead compound for a new generation of potent anti-inflammatory drugs with an improved side-effect profile.

References (22)

  • JA Mitchell et al.

    Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase

  • Cited by (145)

    • Nimesulide analogues: From anti-inflammatory to antitumor agents

      2019, Bioorganic Chemistry
      Citation Excerpt :

      The A’ position was also modified and it was demonstrated that the oxime, 1-hydroxyethyl and 1-aminoethyl analogues showed moderate to excellent anti-inflammatory activity [79]. Flosulide (Fig. 2) is considered a selective COX-2 inhibitor with an IC50 value of 14.7 nM [110]. Further studies aiming to develop flosulide analogues starting from safrole were performed and the results evidenced that two derivatives with a N-methylsulfonamide moiety (Fig. 3A) and the corresponding retrosulfonamide group (Fig. 3B) were more active than nimesulide, having an inhibition of 46% and 43.1% at a dose of 100 µmol/Kg, respectively, in a carrageenan-induced pleurisy assay [76].

    • Assessment of common Nonsteroidal anti-inflammatory medications by whole blood aggregometry: A clinical evaluation for the perioperative setting

      2014, World Neurosurgery
      Citation Excerpt :

      The COX-2 enzyme is typically found within macrophages after inflammatory induction. It is assumed that there is little to no effect on platelets with the use of the COX-2 medications (14, 18, 21, 33, 35), although some newer medications have been found to retain some platelet TXA2 inhibitory properties, generally on several orders of magnitude lower than the conventional NSAIDs (14, 33). There is little multidisciplinary literature correlating non-ASA NSAID use with perioperative bleeding.

    • Perioperative Administration of Selective Cyclooxygenase-2 Inhibitors for Postoperative Pain Management in Patients After Total Knee Arthroplasty

      2013, Journal of Arthroplasty
      Citation Excerpt :

      Previous studies have shown that conventional preoperative use of nonselective NSAIDs increase bleeding risks [43,44]. Conventional nonselective NSAIDs reversibly inhibit COX and interfere with platelet functions, whereas selective COX-2 inhibitors have less antiplatelet effects than conventional nonselective NSAIDs [45,46]. Analysis of 4 studies shows no difference in blood loss between groups [19,22,28,29], thus confirming indirectly that selective COX-2 inhibitors have little effect on serum thromboxane or platelet functions [18].

    • European perspectives on upcoming analgesics: What do they have that we don't-and what do they think about them?

      2010, Techniques in Regional Anesthesia and Pain Management
      Citation Excerpt :

      Diclofenac has an acidity constant of 4.0, a partition coefficient of 13.4, and structural elements that include a phenyacetic acid group, a secondary amino group, and a phenyl ring containing chlorine atoms, which induce a large angle of torsion between the rings. Alteration of any of these elements in analogs results in a decrease in biological activity.61 Diclofenac produces a relatively nonselective inhibition of the cyclooxygenase isozymes COX-1 and COX-2 (the measured ratio of selectivity for COX-2 over COX-1 ranges from about 1.4-to about 26-fold in the studies cited).

    • The role of the cylooxygenase pathway in nociception and pain

      2006, Seminars in Cell and Developmental Biology
    View all citing articles on Scopus
    View full text